American Association for Cancer Research
mct-23-0437_figure_s3_supps3.docx (439.67 kB)

Figure S3 from Improving Intracellular Delivery of an Antibody–Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo

Download (439.67 kB)
journal contribution
posted on 2024-03-04, 21:06 authored by Ian Nessler, Baron Rubahamya, Anna Kopp, Scott Hofsess, Thomas M. Cardillo, Nalini Sathyanarayan, Jennifer Donnell, Serengulam V. Govindan, Greg M. Thurber

SE-HPLC Plot XAb-SN-38. HPLC detection at 360 nm, SN-38 absorbance region, with 100% associated with the peak corresponding to the antibody.


ImmunoMedics (Immunomedics Inc)

National Institutes of Health (NIH)



Solid tumor antibody–drug conjugates (ADC) have experienced more clinical success in the last 5 years than the previous 18-year span since the first ADC approval in 2000. While recent advances in protein engineering, linker design, and payload variations have played a role in this success, high expression and readily internalized targets have also been crucial to solid tumor therapy. However, these factors are also paradoxically connected to poor tissue penetration and lower efficacy. Previous work shows that potent ADCs can benefit from slower internalization under subsaturating doses to improve tissue penetration and increase tumor response. In contrast, faster internalization is predicted to increase efficacy under higher, tumor saturating doses. In this work, the intracellular delivery of SN-38 conjugated to an anti-carcinoembryonic antigen (anti-CEA) antibody (Ab) is increased by coadministering a noncompeting (cross-linking) anti-CEA Ab to improve efficacy in a colorectal carcinoma animal model. The SN-38 payload enables broad tumor saturation with clinically-tolerable doses, and under these saturating conditions, using a second CEA receptor cross-linking Ab yields faster internalization, which increases tumor killing efficacy. Our spheroid results show indirect bystander killing can also occur, but the more efficient direct cell killing from targeted intracellular payload release drives a greater tumor response. These results provide a strategy to increase therapeutic effectiveness with improved intracellular delivery under tumor saturating doses with the potential to expand the ADC target repertoire.

Usage metrics

    Molecular Cancer Therapeutics



    Ref. manager